Citations

Clear

99 citation(s) found for "Romano, D".

Conventional versus advanced imaging selection for endovascular treatment of basilar artery occlusion strokes
Chen, Huanwen , Colasurdo, Marco, Matsukawa, Hidetoshi, Cunningham, Conor, Maier, Ilko , Kasab, Sami Al, Jabbour, Pascal , Kim, Joon-Tae, Wolfe, Stacey Quintero, Rai, Ansaar, Starke, Robert M, Psychogios, Marios-Nikos, Goyal, Nitin, Yoshimura, Shinichi, Cuellar, Hugo, Grossberg, Jonathan A, Alawieh, Ali, Alaraj, Ali, Ezzeldin, Mohamad, Romano, Daniele G, Tanweer, Omar, Mascitelli, Justin, Fragata, Isabel, Polifka, Adam, Siddiqui, Fazeel, Osbun, Joshua, Crosa, Roberto, Matouk, Charles, Park, Min S, Levitt, Michael R, Brinjikji, Waleed, Moss, Mark, Dumont, Travis, Daglioglu, Ergun, Williamson, Richard, Navia, Pedro, Leacy, Reade De, Chowdhry, Shakeel, Altschul, David J, Spiotta, Alejandro M, Kan, Peter, Wolfe, Stacey Q , Alaraj, Ali , Altschul, David , Samaniego, Edgar A , Jabbour, Pascal , Alaraj, Ali , Altschul, David J , Wolfe, Stacey Quintero , Chen, Huanwen , Colasurdo, Marco, Matsukawa, Hidetoshi, Cunningham, Conor, Kasab, Sami Al, Kim, Joon-Tae, Wolfe, Stacey Quintero, Rai, Ansaar, Starke, Robert M, Psychogios, Marios‐Nikos , Goyal, Nitin, Yoshimura, Shinichi, Cuellar, Hugo, Grossberg, Jonathan A, Alawieh, Ali, Ezzeldin, Mohamad, Romano, Daniele G, Tanweer, Omar, Mascitelli, Justin, Fragata, Isabel, Polifka, Adam, Siddiqui, Fazeel, Osbun, Joshua, Crosa, Roberto, Matouk, Charles, Park, Min S, Levitt, Michael R, Brinjikji, Waleed, Moss, Mark, Dumont, Travis, Daglioglu, Ergun, Williamson, Richard, Navia, Pedro, Leacy, Reade De, Chowdhry, Shakeel, Spiotta, Alejandro M, Kan, Peter

Mayo Clinic

European Stroke Journal | January 20, 2026 | Volume: 11 | Issue: 1 | Pages: No page available

10.1093/esj/23969873251364973 | PMID 41614473 Get It

Abstract Introduction Endovascular thrombectomy (EVT) is an effective treatment for basilar artery occlusion (BAO) stroke in select patients. While there is a growing body of literature suggesting that advanced imaging modalities such as computed tomography perfusion (CTP) and magnetic resonance (MR) may not be necessary for selecting anterior circulation large vessel occlusion stroke patients for EVT, whether advanced imaging may be superior to conventional imaging (non-contrast CT and CT angiography) in identifying good treatment candidates among BAO patients is less clear. Patients and methods This was a multicenter retrospective cohort study of BAO EVT patients treated from 2013 to 2022 in the Stroke Thrombectomy and Aneurysm Registry. Patients selected for EVT by advanced imaging (CTP or MR) were matched with those selected by conventional imaging using propensity score matching (PSM) accounting for possible confounders. Primary outcome was functional independence at 90 days. Other outcomes include bedridden state or death at 90-days and symptomatic intracranial hemorrhage (sICH). Results 268 patients were included. 150 patients were selected for BAO EVT by conventional imaging, 86 by CTP, and 32 by MR. Patients selected by advanced imaging were significantly older than those selected by conventional imaging (median age 71 vs 64 years, p = 0.001); patient characteristics were otherwise similar between cohorts. After PSM, 90-day outcomes were similar between the two cohorts (p = 0.56), with similar rates of functional independence (39.4% vs 35.1%, p = 0.65), bedridden state or death (40.4% vs 44.7%, p = 0.66), and sICH (3.3% vs 5.7%, p = 0.49) for conventional and advanced imaging groups, respectively. Results were similar across treatment time windows (all p > 0.05). Conclusions Selecting patients for basilar EVT using conventional versus advanced imaging did not result in different clinical outcomes, regardless of treatment time windows. Conventional imaging appears sufficient as a first-line tool for selecting basilar EVT patients in routine clinical practice.
Frontline aspiration versus stent retriever thrombectomy for M2 occlusions: Insights from the STAR registry
Gaub, Michael , Kasem, Rahim Abo , Maier, Ilko , Rai, Ansaar, Jabbour, Pascal, Kim, Joon-Tae, Wolfe, Stacey Q , Starke, Robert M, Psychogios, Marios-Nikos, Goyal, Nitin, Dye, Justin , Alaraj, Ali, Ezzeldin, Mohamad , Yoshimura, Shinichi, Fiorella, David, Tanweer, Omar, Romano, Daniele G, Navia, Pedro, Cuellar, Hugo H, Polifka, Adam , Osbun, Joshua, Siddiqui, Fazeel , Moss, Mark, Mokin, Maxim, Matouk, Charles, Park, Min S, Brinjikji, Waleed, Dağlıoğlu, Ergün , Williamson, Richard, Altschul, D, Ogilvy, Christopher S, Levitt, Michael R, Gory, Benjamin, Paul, A, Kan, Peter, Casagrande, Walter, Chowdhry, Shakeel, Stiefel, Michael , Grandhi, Ramesh, Spiotta, Alejandro M , Mascitelli, Justin, Jabbour, Pascal , Ogilvy, Christopher S. , Alaraj, Ali , Altschul, David , Abo Kasem, Rahim , Jabbour, Pascal , Alaraj, Ali , Altschul, David J , Wolfe, Stacey Quintero , Ogilvy, Christopher S , Rai, Ansaar , Kim, Joon‐Tae , Howard, Brian M , Alawieh, Ali , Psychogios, Marios‐Nikos , Shaban, Amir , Fiorella, David , Tanweer, Omar , Romano, Daniele Giuseppe , Navía, Pedro , Fragata, Isabel , Osbun, Joshua W , Moss, Mark, Limaye, Kaustubh , Mokin, Maxim , Matouk, Charles , Brinjikji, Waleed , Williamson, Richard, Crosa, Roberto , Levitt, Michael R. , Gory, Benjamin , Paul, Alexandra R , Chowdhry, Shakeel , Grandhi, Ramesh , Mascitelli, Justin R

Mayo Clinic

European Stroke Journal | January 20, 2026 | Volume: 11 | Issue: 1 | Pages: No page available

10.1093/esj/23969873251381924 | PMID 41614461 Get It

Abstract Background Recent trials have furthered uncertainty regarding the endovascular benefit for medium vessel occlusions (MeVO). Stent retrievers (SR) were employed in the first attempt in most interventional arm participants. We sought to compare outcomes in acute MCA M2 occlusions between frontline aspiration and SR, and to delineate procedural and anatomical covariates associated with differential treatment effect. Methods Retrospective analysis of a multicenter stroke thrombectomy cohort identified cases of MT for M2 occlusions. Unmatched and propensity score-matched (PSM) cohorts were generated comparing frontline aspiration to standalone and combined SR. The primary outcome was functional independence (mRS 0–2) at 90 days. Recanalization, symptomatic intracranial hemorrhage (sICH), mortality, and the effect of M2 laterality, division occlusion and procedure time were assessed. Results About 1734 patients with M2 occlusions underwent either frontline aspiration (n = 711) or SR/combined (n = 958) thrombectomy between 2013 and 2024. PSM analysis favored aspiration for functional independence (49.9% vs 44.0%, OR 1.27 (1.03–1.57)), complete recanalization (61.2% vs 48.7%, OR 1.66 (1.34–2.05)), complete first pass effect (35.0% vs 27.6%, OR 1.42 (1.13–1.78)), and sICH (3.5% vs 6.2%, OR 0.55 (0.33–0.91)), with no difference in mortality. Frontline aspiration had significantly shorter procedural times (median 28 [IQR 15–49.5] vs 51 [IQR 35–78] minutes; p < 0.001). For every minute increase in procedure time, the probability of functional independence decreased significantly (p < 0.001) less with frontline aspiration (0.35%) compared to SR/combined (1.61%). Conclusion Frontline aspiration for M2 occlusions resulted in better clinical and angiographic outcomes compared to SRs. Future trials for MeVO with a focus on contact aspiration thrombectomy may succeed where recent trials have failed.
Management of splanchnic venous thrombosis after splenectomy in hematologic diseases: systematic review, meta-analysis, and consensus guidelines
Lluís, Núria , Kunzler, F. , Asbun, Domenech , Manresa‐Rocamora, Agustín , Blasco‐Peris, Carles , Alseidi, Adnan, Chan, Carlos , Conrad, Claudius, Ferrone, Cristina R. , Telem, Dana A. , Vega, Eduardo A. , Romano, Fabrizio, Khatkov, I. E. , Conlon, Kevin C. , Feldman, Liane S. , Barabanshikova, Maria V., Giménez, Mariano , Hilal, Mohammad Abu, Dimachk, M., Gangaraju, Radhika , Mehta, Rakesh, Ross, Sharona , Perretta, Silvana , Taner, Timuçin , Shen, Yu‐Min, Demetrashvili, Zaza , Nagalla, Srikanth, Asbun, Horacio J. , Chan, Carlos H.F. , Chan, Carlos H F , Tsamalaidze, Levan , Teh, Catherine , Conrad, Claudius , Targarona, Eduardo M. , Reitano, Elisa , Dudina, Galina A. , Al‐Samkari, Hanny , Freed, Jason A. , Cappellini, Maria Domenica , Nakamura, Masafumi , Lim, Ming Y , Hilal, Mohammad Abu , Alexakis, N. , de’Angelis, Nicola , Bouvy, Nicole D. , Marco, Pascual , Llamas, Pilar , Sánchez-Cabús, Santiago , Lluı́s, Fèlix

Mayo Clinic

International Journal of Surgery | December 19, 2025 | Volume: 112 | Issue: 3 | Pages: 5604-5614

10.1097/js9.0000000000004485 | PMID 41417989 Get It

Background: Splanchnic venous thrombosis (SVT) is a potentially severe and frequently underdiagnosed complication following splenectomy in patients with hematologic diseases. Despite its clinical importance, no standardized, evidence-based guidelines currently exist to inform perioperative prevention, diagnosis, or treatment in this population. Materials and Methods: A systematic review and meta-analysis were conducted following PRISMA guidelines to estimate the incidence and risk factors for SVT after splenectomy in patients with hematologic diseases. Twenty-eight observational studies comprising 5025 patients were included. Risk factor data were analyzed using random-effects models. In parallel, an international Delphi consensus process was performed involving 35 experts (hematologists and surgeons) from 14 countries. Experts were assigned to five domain-specific groups and developed clinical statements on prophylaxis, diagnosis, and management of SVT. Consensus was defined as ≥80% agreement, and recommendations were graded using the GRADE framework. Results: The pooled incidence of SVT after splenectomy was 11.4%, with higher rates in studies using routine imaging (20.7%) and those conducted at single centers (15.1%). Splenic size and weight were significant risk factors, while age, BMI, and platelet count were not. Disease-specific risk was highest in patients with myeloproliferative neoplasms, lymphoma, and thalassemia. The Delphi process generated 25 consensus statements, 14 of which were classified as strong recommendations. Key guidance included perioperative vaccination, individualized thromboprophylaxis with BMI-adjusted low molecular weight heparin, selective Doppler-based screening in high-risk patients, and stepwise anticoagulation regimens based on thrombus burden and clinical evolution. Conclusion: This study presents the first international consensus-based guidelines for managing SVT after splenectomy in patients with hematologic disease. Developed through systematic evidence synthesis and expert consensus, these recommendations provide a practical framework rather than definitive standards of care and support individualized prevention, detection, and treatment strategies in this high-risk population.
Efficacy and safety results from the primary analysis of the pivotal summit trial: Bezuclastinib in adults with non-advanced systemic mastocytosis
Rein, Lindsay , Boggs, Nathan A. , Yi, Cecilia Y. Arana , Elberink, Hanneke Oude , Radia, Deepti , Reiter, Andreas , Piris‐Villaespesa, Miguel , Dybedal, Ingunn , Panse, Jens , Vachhani, Pankit , Kirshenbaum, Arnold S. , Vaughn, Jennifer E. , Cerquozzi, Sonia , Fahrenholz, John M., Pomares, Helena , Üstün, Celalettin , Herrscher, Richard, Barète, Stéphane , Rivera, Candido E., Vadas, Peter , McCulloch, Derek, Keohane, Clodagh, Schafhausen, Philippe, Pilla, Amanda, Zhang, Jenna, Sun, Lei , Shah, Nisha , Jolin, Hina, Easton, Rachael, Sachs, Jessica, Bose, Prithviraj , Modena, Brian D. , Sabato, Vito , Hartmann, Karin , Akin, Cem , George, Tracy I. , Yi, Cecilia Arana , Oh, Stephen T. , Hunter, Anthony M. , Castells, Mariana , Livideanu, Cristina Bulai , Daele, Paul Van , Álvarez‐Twöse, Iván , Taparia, Minakshi , Mital, Andrzej , Hus, Marek , Romano, Alessandra , Lansigan, Frederick , Papayannidis, Cristina , Rondoni, Michela , Manning, Michael, Guilarte, Mar , Bernstein, Jonathan A. , Elena, Chiara , Orfali, Nina M. , Mannelli, Francesco , Shah, Nisha, Siebenhaar, Frank , DeAngelo, Daniel J.

Mayo Clinic

Blood | December 4, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 80-80

10.1182/blood-2025-80 Get It

Abstract Background: Systemic mastocytosis (SM) comprises a spectrum of subtypes characterized by neoplastic mast cell (MC) infiltration of tissues and release of MC mediators. Non-advanced SM (NonAdvSM), including indolent SM (ISM), smoldering SM (SSM), and bone marrow mastocytosis (BMM) subtypes, is the most prevalent form of SM. NonAdvSM can be associated with debilitating symptomology which can significantly impair quality of life. The gain-of-function somatic KIT c.2447 C>T (p.D816V) mutation is found in up to 95% of patients with SM. Bezuclastinib (CGT9486) is an oral, potent, and selective type 1 tyrosine kinase inhibitor with activity against KIT D816V. Results from Summit (NCT05186753) Part 1 informed the recommended phase 2 dose (100 mg QD bezuclastinib) for Part 2. We report topline results from the 24-week assessment of Summit Part 2. Methods: Summit is a multi-center, randomized, double-blind, placebo (PBO)-controlled Phase 2 trial of bezuclastinib in patients with NonAdvSM who had inadequate symptom control despite best supportive care (BSC) medications. The primary endpoint was 24-week mean change from baseline in Mastocytosis Symptom Severity Daily Diary (MS2D2) total symptom score (TSS) (range 0–110), which is a fit-for-purpose patient-reported outcome measure of NonAdvSM symptom severity. Key secondary endpoints included the proportion of patients with ≥50% reduction in serum tryptase, KIT p.D816V variant allele frequency (VAF), bone marrow (BM) MC burden, and MS2D2 TSS, ≥30% TSS reduction. Patients were randomized 2:1 to receive 100mg QD bezuclastinib + BSC or PBO + BSC. Results: As of May 22, 2025, 179 patients were enrolled in Part 2: 119 were randomized to receive bezuclastinib and 60 to placebo. Patients enrolled were representative of the NonAdvSM population with moderate to severe symptoms. Median age (range) was 51 (23-78) years; 65.9% female; mean (SD) baseline MS2D2 TSS 55.6 (19.8); 82% of patients had ISM, 11% had BMM, and 7% had smoldering SSM. At baseline, median (range) KIT p.D816V VAF in whole blood, BM MC burden, and serum tryptase was 0.25% (0-34%), 10% (1-75%), and 40 (6-692) ng/mL, respectively. Bezuclastinib demonstrated statistically significant superiority to placebo on all primary and key secondary endpoints. At Week 24, bezuclastinib led to significantly greater symptom improvement vs placebo (LS mean [95% CI] MS2D2 TSS change: –24.3 [–27.6 to –21.1] vs –15.4 [–19.6 to –11.2]; placebo-adjusted difference: –8.9 points; P=0.0002). A ≥50% reduction in serum tryptase was achieved in 87.4% of bezuclastinib-treated patients vs 0% on placebo (P<0.0001). Significantly more patients receiving bezuclastinib achieved ≥50% reductions in KIT D816V VAF, serum tryptase, BM MCs (P<0.0001), MS2D2 TSS (P=0.01), and ≥30% reduction in MS2D2 TSS (P=0.0004). Most treatment-emergent adverse events (TEAEs) were low grade (gr; 70% Gr 1) and reversible. The most common TEAEs (≥10%) in any treatment group and occurring in greater frequency in the bezuclastinib arm were hair color changes (69.5% vs 5.0%), altered taste (23.7% vs 0%), nausea (22.0% vs 13.3%), increased ALT/AST (22.0% vs 6.6%), headache (17.8% vs 11.7%), alopecia (11.9% vs 3.3%), and increased ALP (10.2% vs 3.3%). TEAEs (≥10%) that occurred more often in the placebo group were diarrhea (13% vs 18%), dizziness (10% vs 12%), fatigue (7% vs 12%), and arthralgia (6% vs 15%). ALT/AST elevations ≥Gr 3 were experienced by 5.9% of patients. The only hepatic adverse events (AEs) reported were transient lab abnormalities; none required hospitalization. Treatment-related AEs requiring dose reductions occurred in 11% of patients receiving bezuclastinib. All discontinuations (5.9%) due to treatment-related AEs were due to transaminase elevations; all fully resolved. Conclusions: At 24-weeks, bezuclastinib 100 mg QD demonstrated statistically and clinically significant improvements in symptom burden and biomarkers of disease vs placebo in patients with NonAdvSM. The treatment was generally well-tolerated and effective across a population that is representative of the real-world NonAdvSM population, including SSM. These results support the use of bezuclastinib to reduce SM burden and symptoms in pts with NonAdvSM, and a potentially disease-modifying impact.
Abstract 245: Super‐Large‐Bore vs Large‐Bore Aspiration Catheters in Mechanical Thrombectomy: A Multicenter Propensity‐Matched Analysis
Chacon, Alexander , Inoa, Violiza , Cawley, M. F., Rai, Ansaar , Maier, Ilko , Dye, J. A., Ezzeldin, M., Matouk, Charles, Brinjikji, Waleed , Jabbour, Pascal , Almallouhi, E., Dağlıoğlu, Ergün , Spiotta, Alejandro M , Grossberg, Jonathan A , Chacon, A., Alawieh, Ali , Motiwala, Mustafa , Arthur, Adam Stephen , Cawley, M., Howard, Brian M , Siddiqui, F., Alaraj, Ali , Romano, Daniele Giuseppe , Fiorella, David , Dye, J., Wolfe, Stacey Q , Mascitelli, Justin R , Fragata, Isabel , Limaye, Kaustubh , Ogilvy, Christopher S. , Jabbour, Pascal , Almallouhi, Eyad , Park, M. S., Navía, Pedro , Grandhi, Ramesh , Altschul, David , Schirmer, Clemens M. , Paul, Alexandra R , Mokin, Maxim , Goyal, Nitin

Mayo Clinic

Stroke: Vascular and Interventional Neurology | December 2, 2025 | Volume: 5 | Issue: S1 | Pages: No page available

10.1161/svi270000_245 Get It

Background Contact aspiration remains a frontline approach for mechanical thrombectomy (MT) in acute ischemic stroke (AIS). Early evidence correlates catheter size with procedural efficiency and clinical outcomes. Larger‐bore (LB) aspiration catheters may enhance clot ingestion, increase aspiration force, and facilitate faster and more complete recanalization. However, the transition from standard LB catheters (0.068‐0.072″) to super‐large‐bore (SLB, ≥0.080″) devices has raised questions regarding both safety and clinical benefit. Although the use of SLB catheters is increasing, comparative data on their performance versus LB catheters remain limited. This study aims to evaluate the safety and efficacy of SLB compared with LB catheters including data from a large multicenter international registry. Methods We retrospectively analyzed patients with AIS due to LVO treated at 46 international stroke centers between January 2013 and June 2025. Among eligible patients, propensity score matching (PSM) at a 5:1 ratio was used to balance baseline characteristics between those treated with standard LB catheters and those treated with SLB catheters. Safety endpoints included intraprocedural complications, symptomatic intracranial hemorrhage (sICH), distal embolization, and 90‐day mortality. Efficacy endpoints included functional independence at 90 days (modified Rankin Scale [mRS] 0‐2), successful recanalization (TICI ≥2b), first‐pass effect (TICI ≥2b on the first aspiration attempt), and procedural timing to TICI2b. Results A total of 3,100 patients were included (LB n=3,024; SLB n=67). After PSM (LB n=335; SLB n=67), safety outcomes were comparable between groups in terms of intraprocedural complications occurred (p=0.5), sICH (p>0.9), embolization to new territory (p=0.2), and 90‐day mortality (p>0.9). Efficacy outcomes were similarly consistent for functional independence (mRS 0‐2) (p>0.9), successful recanalization (p>0.9), first‐pass effect (p=0.5), and time to TICI ≥2b (27.6 vs. 24.5 minutes; p=0.9). These findings remained consistent in the subgroup with ICA and M1 occlusions, with no significant differences in safety (intraprocedural complications [p=0.4], sICH [p>0.9], embolization to new territory [p=0.6], or 90‐day mortality [p>0.9], nor in efficacy outcomes (functional independence at 90 days [p>0.9], successful recanalization [p=0.9], first‐pass effect [p=0.6], and time to TICI ≥2b [p=0.9]). Conclusion In this large multicenter analysis, the use of SLB aspiration catheters demonstrated comparable safety and efficacy to standard LB catheters for MT in AIS. Despite theoretical advantages in aspiration dynamics, SLB devices did not confer significant procedural or clinical benefit over LB catheters. These findings suggest that while SLB catheters are a feasible alternative, technical and clinical outcomes remain comparable to LB catheters. Further prospective studies are warranted to clarify potential clinical advantages. image
Procedure duration predicts outcomes more than prehospital delay in endovascular stroke treatment
Saad, Hassan , Koo, Andrew B. , Grossberg, Jonathan A , Tianwen, Ma, Howard, Brian M. , Sowlat, Mohammad‐Mahdi , Baba, Bachar El , Chacón, Ariana , Jabbour, Pascal , Rai, Ansaar , Dye, Justin , Alaraj, Ali , Cawley, C. Michael , Tong, Frank , Akbik, Feras , Pabaney, Aqueel, Ezzeldin, Mohamad , Kim, Joon‐Tae , Siddiqui, Fazeel , Maier, Ilko , Park, Min S. , Psychogios, Marios‐Nikos, Wolfe, Stacey Q , Starke, Robert M. , Tanweer, Omar , Polifka, Adam , Mokin, Maxim, Brinjikji, Waleed , Dağlıoğlu, Ergün , Williamson, Richard , Altschul, David , Ogilvy, Christopher S. , Crosa, Roberto , Gory, Benjamin , Kan, Peter , Casagrande, Walter, Chowdhry, Shakeel , Stiefel, Michael , Spiotta, Alejandro M , Ma, Tianwen , El Baba, Bachar , Fiorella, David , Yoshimura, Shinichi , Kim, Joon-Tae , Arthur, Adam Stephen , Fragata, Isabel , Siddiqui, Fazeel M , Matouk, Charles , Maier, Ilko , Levitt, Michael R , Grandhi, Ramesh , Wolfe, Stacey Quintero , Shaban, Amir , Navia, Pedro , Osbun, Joshua W , Brinjikji, Waleed , Altschul, David J , Ogilvy, Christopher S , Crosa, Roberto , Paul, Alexandra R , Kan, Peter , Spiotta, Alejandro M , Alawieh, Ali M , Alaraj, Ali , Sowlat, Mohammad-Mahdi , Howard, Brian M , Koo, Andrew B , Chacón-Aponte, Ariana Alejandra , Jabbour, Pascal , Fiorella, David , Yoshimura, Shinichi , Goyal, Nitin , Fragata, Isabel , Mascitelli, Justin R , Matouk, Charles , Levitt, Michael R. , Grandhi, Ramesh , Samaniego, Edgar A , Romano, Daniele G, Navía, Pedro , Cuellar, Hugo , Moss, Mark E, Limaye, Kaustubh , Mokin, Maxim , Gory, Benjamin , Alawieh, Ali

Mayo Clinic

Journal of NeuroInterventional Surgery | September 19, 2025 | Volume: 18 | Issue: 6 | Pages: 1494-1502

10.1136/jnis-2025-023906 | PMID 40973492 Get It

Background Endovascular thrombectomy (EVT) has transformed acute ischemic stroke (AIS) care, with onset-to-puncture (OTP) time widely recognized as a critical determinant of outcome. However, emerging evidence suggests that in-hospital procedure time (PT)—from arterial puncture to final recanalization—may have an equally or more significant impact. This study examines the relative contribution of PT versus OTP to functional outcomes in patients with AIS undergoing EVT. Methods A retrospective analysis was conducted of 6644 patients with AIS treated at 44 international stroke centers from the Stroke Thrombectomy and Aneurysm Registry (STAR; 2016–2023). Multivariable regression, time-equivalence analysis, and marginal effects modeling were used to assess associations between PT, OTP, and 90-day modified Rankin Scale (mRS) outcomes. Centers were stratified by procedural efficiency and compared using propensity score matching (PSM). Mediation analysis evaluated whether PT accounted for inter-center differences. Results PT and OTP were independently associated with functional outcomes; however, PT had a significantly stronger effect (adjusted OR for mRS 0–2: PT=0.56 vs OTP=0.96 per hour). Each 5 min increase in PT was equivalent to 78–100 min of additional OTP in outcome impact. Centers with faster average PT had higher rates of functional independence (number needed to treat (NNT)=10), fewer complications, and lower symptomatic intracranial hemorrhage rates. PT significantly mediated the relationship between center tier and outcomes (Sobel’s P<0.001). Conclusion While minimizing OTP remains important, PT exerts a greater influence on outcomes after EVT. Procedural efficiency should be emphasized in stroke systems of care and included in center performance metrics to improve patient outcomes.
Conventional versus advanced imaging selection for endovascular treatment of basilar artery occlusion strokes
Chen, Huanwen , Maier, Ilko , Jabbour, Pascal , Kim, Joon‐Tae , Wolfe, Stacey Q , Rai, Ansaar , Starke, Robert M. , Psychogios, Marios‐Nikos, Yoshimura, Shinichi , Grossberg, Jonathan A , Alaraj, Ali , Ezzeldin, Mohamad , Tanweer, Omar , Mascitelli, Justin, Fragata, Isabel , Polifka, Adam , Siddiqui, Fazeel , Crosa, Roberto , Matouk, Charles, Park, Min S. , Brinjikji, Waleed , Moss, Mark, Dumont, Travis M., Dağlıoğlu, Ergün , Williamson, Richard , Chowdhry, Shakeel , Altschul, David , Spiotta, Alejandro M , Kan, Peter , Maier, Ilko , Jabbour, Pascal , Samaniego, Edgar A , Crosa, Roberto , Alaraj, Ali , Altschul, David J , Wolfe, Stacey Quintero , Fragata, Isabel , Colasurdo, Marco , Matsukawa, Hidetoshi , Cunningham, Conor M. , Kasab, Sami Al , Goyal, Nitin , Cuellar, Hugo, Alawieh, Ali , Romano, Daniele Giuseppe , Mascitelli, Justin R , Osbun, Joshua W , Levitt, Michael R. , Navía, Pedro , Leacy, Reade De , Chen, Huanwen

Mayo Clinic

European Stroke Journal | August 28, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/23969873251364973 | PMID 40873294 Get It

Introduction: Endovascular thrombectomy (EVT) is an effective treatment for basilar artery occlusion (BAO) stroke in select patients. While there is a growing body of literature suggesting that advanced imaging modalities such as computed tomography perfusion (CTP) and magnetic resonance (MR) may not be necessary for selecting anterior circulation large vessel occlusion stroke patients for EVT, whether advanced imaging may be superior to conventional imaging (non-contrast CT and CT angiography) in identifying good treatment candidates among BAO patients is less clear. Patients and methods: This was a multicenter retrospective cohort study of BAO EVT patients treated from 2013 to 2022 in the Stroke Thrombectomy and Aneurysm Registry. Patients selected for EVT by advanced imaging (CTP or MR) were matched with those selected by conventional imaging using propensity score matching (PSM) accounting for possible confounders. Primary outcome was functional independence at 90 days. Other outcomes include bedridden state or death at 90-days and symptomatic intracranial hemorrhage (sICH). Results: 268 patients were included. 150 patients were selected for BAO EVT by conventional imaging, 86 by CTP, and 32 by MR. Patients selected by advanced imaging were significantly older than those selected by conventional imaging (median age 71 vs 64 years, p = 0.001); patient characteristics were otherwise similar between cohorts. After PSM, 90-day outcomes were similar between the two cohorts ( p = 0.56), with similar rates of functional independence (39.4% vs 35.1%, p = 0.65), bedridden state or death (40.4% vs 44.7%, p = 0.66), and sICH (3.3% vs 5.7%, p = 0.49) for conventional and advanced imaging groups, respectively. Results were similar across treatment time windows (all p > 0.05). Conclusions: Selecting patients for basilar EVT using conventional versus advanced imaging did not result in different clinical outcomes, regardless of treatment time windows. Conventional imaging appears sufficient as a first-line tool for selecting basilar EVT patients in routine clinical practice.
Disparities During Family-Centered Rounds for Families Using Languages Other Than English
Pelpola, Judith S., Rojas, Christina R. , Blakeney, Erin Abu‐Rish , Farkas, Jonathan S. , Everhart, Jennifer L., Fan, Angela L. , Johnson, Tyler , Kajiwara, Yuko, Knoebel, Erin, Lewis, Kheyandra D. , Mallick, Nandini, Markle, Peggy, Romano, Eileen M., Shaughnessy, Erin E. , Calaman, Sharon, Landrigan, Christopher P. , Khan, Alisa , Johnson, Tyler , García, Sonia , Graham, Dionne A. , Johnson, Tyler M., Romano, Eileen M., Baird, Jennifer D. , Spector, Nancy Dollase

Mayo Clinic

Pediatrics | July 28, 2025 | Volume: 156 | Issue: 2 | Pages: No page available

10.1542/peds.2024-070285 | PMID 40716767 Get It

BACKGROUND/OBJECTIVE Patient- and family-centered rounds (PFCR) have become a pediatric standard of care. However, rounds experiences of families using languages other than English (LOE)—particularly languages other than English or Spanish (LOES; eg, Arabic)—receive less focus. We aimed to identify differences in PFCR communication and engagement by language. METHODS We analyzed postintervention data from a 21-center structured PFCR study, assessing communication practices, quality, and family and nurse engagement during PFCR. Logistic regression adjusted by site compared PFCR between families using (1) LOE vs English, (2) Spanish vs English, and (3) LOES vs English. RESULTS Among 3051 PFCR encounters, 348 (11.4%) involved LOE (Spanish = 260; LOES = 85). Interpretation was not used in 7.2%, 5.8%, and 9.4% of encounters using LOE, Spanish, and LOES, respectively. PFCR in the following groups had lower adjusted odds (adjusted odds ratio [95% CI]) for the following domains: (1) LOE vs English: including providing verbal patient summaries (0.66 [0.46–0.95]), explaining diagnoses and differentials (0.62 [0.44–0.88]), family engagement (0.34 [0.20–0.57]), nursing inclusion (0.75 [0.60–0.93]), and nursing engagement (0.69 [0.52–0.90]). (2) Spanish vs English: diagnoses/differentials being explained (0.56 [0.37–0.85]), family engagement (0.35 [0.18–0.67]), nursing inclusion (0.77 [0.59–1.00]), and nursing engagement (0.68 [0.52–0.89]). (3) LOES vs English: families sharing concerns (0.66 [0.47–0.93]), family engagement (0.30 [0.16–0.54]), and nursing inclusion (0.74 [0.55–0.99]). CONCLUSION Even after implementing a PFCR intervention, families using LOE—especially LOES—experienced significant disparities in communication and engagement. Future approaches to improving PFCR should emphasize language access and promote nurse and family engagement for families using LOE, particularly LOES.
TDP-43 pathology induces CD8 + T cell activation through cryptic epitope recognition
Chizari, Shahab , Kong, Steven Lingyang, Saigal, Vidur J., Turchetti, Valentina, Chen, Bingxian, Devine, Connor C., Zampedri, Luca, Skorupinska, Iwona, Minicuci, Giacomo Maria, Paron, Francesca, Tonin, Paola , Marchetto, Giulia, Li, Ziyi , Colón-Mercado, Jennifer M., Barattucci, Simone, Soltic, Darija, Dattilo, Dario, Gatt, Ariana, Hembrador, Jada M., Capasso, Guido, Frezzato, Federica, Trentin, Livio, Lin, Elisabeth, Lopes, Raquel, Routledge, Nathan, Qi, Yue A., Hanna, Michael G., Ward, Michael, Petrucelli, Leonard , Buratti, Emanuele , Machado, Pedro , Fratta, Pietro, Jiang, Ning , Hanna, Michael G. , Ward, Michael E. , Fratta, Pietro , Fratta, Pietro , Kong, Steven , Ward, Michael E , Romano, Maurizio , Machado, Pedro M , Fratta, Pietro , Fratta, Pietro , Zanovello, Matteo , Brown, Anna‐Leigh , Chen, Bingxian, Devine, Connor C., Zampedri, Luca, Skorupinska, Iwona, Minicuci, Giacomo Maria, Paron, Francesca, Marchetto, Giulia, Li, Ziyi, Colón-Mercado, Jennifer M., Barattucci, Simone, Soltic, Darija, Dattilo, Dario, Gatt, Ariana P. , Hembrador, Jada M., Capasso, Guido, Frezzato, Federica, Trentin, Livio, Lin, Elisabeth, Lopes, Raquel, Routledge, Nathan, Qi, Yue A., Hanna, Michael G., Ward, Michael, Vattemi, Gaetano Nicola Alfio , Malaspina, Andrea , Merve, Ashirwad , Sorarú, Gianni , Jiang, Ning

Mayo Clinic

No container title available | June 27, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.22.660773 | PMID 40667053 Get It

Abstract Aggregation and nuclear depletion of the RNA binding protein TDP-43 are the crucial pathological features of amyotrophic lateral sclerosis (ALS) and inclusion body myositis (IBM), two degenerative diseases of the CNS and muscle. The loss of TDP-43 nuclear function results in the aberrant inclusion of cryptic exons in mRNA transcripts, leading to the expression of de novo proteins. Clonally expanded and highly differentiated CD8 + T cells have been observed in individuals with TDP-43 proteinopathies and therapeutics modulating the T cell response have recently been found to extend survival. However, the target antigens mediating T cell activation have remained elusive. Here, we investigate whether the de novo proteins induced by aberrant cryptic splicing due to TDP-43 nuclear loss can act as neo-antigens. We detect the HDGFL2 cryptic peptide and multiple other TDP-43 cryptic exons in IBM skeletal muscle, where their presence correlates with enrichment of T cells and class I antigen presentation pathways. Furthermore, we identify epitopes deriving from HDGFL2 and IGLON5 cryptic peptides which are recognized by clonally expanded and functionally differentiated populations of CD8 + T cells in ALS and IBM Patients. Finally, we demonstrate that T cells engineered to express the identified TCRs can bind and activate in response to the cryptic peptide derived epitopes (cryptic epitopes) and are able to kill TDP-43 deficient astrocytes. This work identifies for the first time specific T cell antigens in ALS and IBM, directly linking adaptive immune response to TDP-43 pathology.